Tipranavir (Aptivus): approval cautiously recommended.
A new protease inhibitor active against most HIV that is resistant to other protease inhibitors is likely to be approved in the U.S. soon, after an 11-3 vote of an advisory committee.
James
John S
JS
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004359:Drug Therapy, Combination; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir